[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-407104-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-407104-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","long-term-control-after-intermittent-reintroduction-of-enfortumab-vedotin-in-metastatic-urothelial-carcinoma-a-case-report","Long-Term Control after Intermittent Reintroduction of Enfortumab Vedotin in Metastatic Urothelial Carcinoma - A Case Report","","Enfortumab vedotin (EV), a nectin-4–targeting antibody-drug conjugate, is used for metastatic urothelial carcinoma after platinum chemotherapy and immune checkpoint inhibitor failure. Adverse events such as skin toxicity can require interruption or dose reduction, raising concerns about efficacy. A 72-year-old woman achieved a durable partial response despite grade 2 skin toxicity. After symptom resolution, EV was reintroduced at a reduced dose and the clinical response was maintained. The case supports AE-guided intermittent rechallenge as a feasible option in selected patients.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/long-term-control-after-intermittent-reintroduction-of-enfortumab-vedotin-in-metastatic-urothelial-carcinoma-a-case-report/407104/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/long-term-control-after-intermittent-reintroduction-of-enfortumab-vedotin-in-metastatic-urothelial-carcinoma-a-case-report/407104.png","ImageObject",300,407,{"name":42,"@type":43},"dabgoudw","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-28",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is enfortumab vedotin used for in this case?","Question",{"text":63,"@type":64},"It is used to treat metastatic urothelial carcinoma after progression following prior therapies, including platinum chemotherapy and immune checkpoint inhibitors.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why was EV temporarily discontinued in this patient?",{"text":68,"@type":64},"Grade 2 skin toxicity required temporary interruption and dose modification to manage adverse events.",{"name":70,"@type":61,"acceptedAnswer":71},"How was EV restarted and what was the outcome?",{"text":72,"@type":64},"After symptom resolution, EV was reintroduced at a reduced dose, and the long-term partial response was maintained.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},407104,1790763458,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":107,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},3985747860484,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Case Reports in Oncology  \n\n| Case Rep Oncol 2026;19:27–33 |  |\n| --- | --- |\n| DOI: 10. 1159/000549571\u003Cbr>Received: September 19, 2025\u003Cbr>Accepted: November 7, 2025\u003Cbr>Published online: December 2, 2025 | © 2025 The Author(s) .\u003Cbr>Published by S. Karger AG, Basel [www.karger.com/cro](www.karger.com/cro) |\n\nThis article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) ([https://karger.com/Services/OpenAccessLicense](https://karger.com/Services/OpenAccessLicense)). Usage and distribution for commercial purposes requires written permission.  \nCase Report  \nLong-Term Control after Intermittent Reintroduction of EnfortumabVedotin in Metastatic Urothelial Carcinoma:  \nA Case Report  \nKenta Fujii Suguru Shirotake Shohei Yamamura Daisuke Igarashi Takayuki Takahashi Yuta Umezawa Kimiharu Takamatsu Masayuki Hagiwara Go Kaneko Masafumi Oyama  \nDepartment of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan  \nKeywords  \nMetastatic urothelial carcinoma · Enfortumab vedotin · Intermittent reintroduction · Durable disease control · Adverse event management  \nAbstract  \nIntroduction: Enfortumab vedotin (EV), an antibody-drug conjugate targeting Nectin-4, has become a standard treatment option for metastatic urothelial carcinoma (mUC) following failure of platinum-based chemotherapy and immune checkpoint inhibitors. However, adverse events (AEs) such as skin toxicity often necessitate dose modification or temporary discontinuation. Case Presentation: We report the case of a 72-year-old woman with mUC who achieved a long-term partial response to EV despite experiencing grade 2 skin toxicity that required temporary treatment interruption. After symptom resolution, EV was successfully reintroduced at a reduced dose, and clinical response was maintained. Conclusion: Temporary discontinuation of EV due to AEs followed by intermittent reintroduction resulted in long-term disease control in this patient with mUC. This case suggests that rechallenging EV after treatment interruption may be a feasible approach in selected patients, underscoring the importance of careful AE management in real-world practice.  \n© 2025 The Author(s) .  \nPublished by S. KargerAG, Basel  \nCorrespondence to:  \nSuguru Shirotake, ss6001  [5931.saitama-med.ac.jp](5931.saitama-med.ac.jp)  \nCase Reports in Oncology  \nCase Rep Oncol 2026;19:27–33 28  \n\n| DOI: 10. 1159/000549571 | © 2025 The Author(s) . Published by S. Karger AG, Basel [www.karger.com/cro](www.karger.com/cro) |\n| --- | --- |\n\nFujii et al.: Intermittent Reintroduction of Enfortumab Vedotin in mUC  \nIntroduction  \nEnfortumab vedotin (EV), an antibody-drug conjugate targeting Nectin-4, has demonstrated significant efficacy in patients with metastatic urothelial carcinoma (mUC) who have progressed after platinum-based chemotherapy and immune checkpoint inhibitors. The EV-301 trial showed a survival benefit of EV over standard chemotherapy, leading to its widespread adoption in clinical practice [1] .  \nHowever, EV is frequently associated with treatment-related adverse events (AEs), such as skin rash, peripheral neuropathy, and fatigue, which may necessitate dose reduction or treatment interruption [1] . Although such AEs often raise concerns regarding compromised efficacy, emerging evidence suggests that patients may still derive substantial benefit from EV despite reduced relative dose intensity (RDI) .  \nWe report a case of mUC with a long-term partial response to EV, despite temporary treatment interruption and dose reduction due to skin toxicity. This case highlights the clinical relevance of individualized dose management and the potential for successful reinitiation of EV following AE-related discontinuation.  \nCase Presentation  \nA 72-year-old Japanese woman was referred to our department for evaluation of rightsided hydronephrosis identified on routine ultrasound. She had no notable medical or family history. Blood tests r","cbCaiuGyXlIOAsnC","https://ap.wps.com/l/cbCaiuGyXlIOAsnC","pdf",2501919,"English","# Introduction\n## Case Presentation\n## Conclusion","[{\"question\":\"What is enfortumab vedotin used for in this case?\",\"answer\":\"It is used to treat metastatic urothelial carcinoma after progression following prior therapies, including platinum chemotherapy and immune checkpoint inhibitors.\"},{\"question\":\"Why was EV temporarily discontinued in this patient?\",\"answer\":\"Grade 2 skin toxicity required temporary interruption and dose modification to manage adverse events.\"},{\"question\":\"How was EV restarted and what was the outcome?\",\"answer\":\"After symptom resolution, EV was reintroduced at a reduced dose, and the long-term partial response was maintained.\"}]","Long-Term Control after Intermittent Reintroduction of Enfortumab Vedotin in Metastatic Urothelial Carcinoma - A Case Report | PDF",1790570329,18]